Cargando…
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
Tyrosine kinase inhibitors (TKIs) are used to target dysregulated signaling pathways in virtually all hematologic malignancies. Many of the targeted signaling pathways are also essential in nonmalignant immune cells. The current coronavirus severe acute respiratory syndrome coronavirus 2 pandemic ca...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871903/ https://www.ncbi.nlm.nih.gov/pubmed/33560402 http://dx.doi.org/10.1182/bloodadvances.2020003768 |